Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA-02: palazestrant + ribociclib versus letrozole + ribociclib in first-line ER-positive/HER2-negative advanced breast cancer
NL-OMON60295Phase 3Recruiting
- Sponsor
- Olema Oncology
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of palazestrant, ribociclib and letrozole in breast cancer (2 arms), sponsored by Olema Oncology. Primary endpoint: Progression-free survival. Started Feb 2026; status: recruiting.
02
Drugs
palazestrantribociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60295.